Author

E. Sharon

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Validating LLM judges for automated oversight of patient communication

LLMs are increasingly used to mediate patient communication, yet scalable evaluation of their safety, accuracy, and communication quality remains an open problem. LLM judges have emerged as automated evaluators, but whether they can holistically replicate human expert judgment is unvalidated. Informed consent for clini...

Zi-Du Xu, Johnathan Zeng, Shuang Zhou et al. · medRxiv · 0 citations

Aug 2026

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

BACKGROUND Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...

F. Pecci, Xinan Wang, Valentina Santo et al. · Journal of Thoracic Oncology · 0 citations

Open access Sep 2026

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their clinical impact is limited by immune-related adverse events (irAEs), therapeutic resistance, and the lack of reliable predictive biomarkers, contributing to a shift from early promise to a therapeutic plateau. irAEs affect multiple organ s...

Joud Hajjar, B. Stephen, A. Aaroe et al. · Journal of Immunotherapy and... · 1 citation